Literature DB >> 21344386

Progesterone utilizes distinct membrane pools of tissue factor to increase coagulation and invasion and these effects are inhibited by TFPI.

Soledad Henriquez1, Claudia Calderon, Marisol Quezada, Bárbara Oliva, Maria Loreto Bravo, Evelyn Aranda, Sumie Kato, Mauricio A Cuello, Jorge Gutiérrez, Andrew F G Quest, Gareth I Owen.   

Abstract

Tissue factor (TF) serving as the receptor for coagulation factor VII (FVII) initiates the extrinsic coagulation pathway. We previously demonstrated that progesterone increases TF, coagulation and invasion in breast cancer cell lines. Herein, we investigated if tissue factor pathway inhibitor (TFPI) could down-regulate progesterone-increased TF activity in these cells. Classically, TFPI redistributes TF-FVII-FX-TFPI in an inactive quaternary complex to membrane associated lipid raft regions. Herein, we demonstrate that TF increased by progesterone is localized to the heavy membrane fraction, despite progesterone-increased coagulation originating almost exclusively from lipid raft domains, where TF levels are extremely low. The progesterone increase in coagulation is not a rapid effect, but is progesterone receptor (PR) dependent and requires protein synthesis. Although a partial relocalization of TF occurs, TFPI does not require the redistribution to lipid rafts to inhibit coagulation or invasion. Inhibition by TFPI and anti-TF antibodies in lipid raft membrane fractions confirmed the dependence on TF for progesterone-mediated coagulation. Through the use of pathway inhibitors, we further demonstrate that the TF up-regulated by progesterone is not coupled to the progesterone increase in TF-mediated coagulation. However, the progesterone up-regulated TF protein may be involved in progesterone-mediated breast cancer cell invasion, which TFPI also inhibits.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21344386     DOI: 10.1002/jcp.22689

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  6 in total

1.  TFPI inhibits breast cancer progression by suppressing ERK/p38 MAPK signaling pathway.

Authors:  Mengying Xing; Ying Yang; Jiaxue Huang; Yaqun Fang; Yucui Jin; Lingyun Li; Xiang Chen; Xiaoxia Zhu; Changyan Ma
Journal:  Genes Genomics       Date:  2022-05-14       Impact factor: 2.164

Review 2.  Breast cancer phenotypes regulated by tissue factor-factor VII pathway: Possible therapeutic targets.

Authors:  Shiro Koizume; Yohei Miyagi
Journal:  World J Clin Oncol       Date:  2014-12-10

Review 3.  Effects of omega-3 fatty acids on progestin stimulation of invasive properties in breast cancer.

Authors:  Michael R Moore; Rebecca A King
Journal:  Horm Cancer       Date:  2012-07-26       Impact factor: 3.869

4.  TFPI1 mediates resistance to doxorubicin in breast cancer cells by inducing a hypoxic-like response.

Authors:  Gerald F Davies; Arnie Berg; Spike D L Postnikoff; Heather L Wilson; Terra G Arnason; Anthony Kusalik; Troy A A Harkness
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

5.  Changes in coagulation and fibrinolytic indices in women with polycystic ovarian syndrome undergoing controlled ovarian hyperstimulation.

Authors:  Ying Huang; Yong Zhao; Ling Yan; Yun-Hai Chuai; Ling-Ling Liu; Yi Chen; Min Li; Ai-Ming Wang
Journal:  Int J Endocrinol       Date:  2014-10-13       Impact factor: 3.257

6.  Role of the short isoform of the progesterone receptor in breast cancer cell invasiveness at estrogen and progesterone levels in the pre- and post-menopausal ranges.

Authors:  Thomas McFall; Mugdha Patki; Rayna Rosati; Manohar Ratnam
Journal:  Oncotarget       Date:  2015-10-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.